dpy-19 Antibody

What is the DPY-19 protein family and what are its key members?

The DPY-19 protein family derives its name from the Caenorhabditis elegans dpy-19 gene (dumpy-19), which affects body morphology in this model organism. In humans, this family consists of four paralogs: DPY19L1, DPY19L2, DPY19L3, and DPY19L4 . These transmembrane proteins function as C-mannosyltransferases that catalyze the attachment of mannose to specific tryptophan residues in target proteins. DPY19L3, for instance, has been demonstrated to mediate C-mannosylation of substrate proteins like RPE-spondin (RPESP) . The proteins show varying degrees of evolutionary conservation, with research indicating high sequence homology between human DPY19L2 and its orthologs in other mammals, ranging from 93-100% identity across species including cow, dog, guinea pig, horse, mouse, rabbit, and rat .

What biological functions have been associated with DPY-19 family proteins?

DPY-19 family proteins primarily function as C-mannosyltransferases, facilitating post-translational modifications critical for protein stability, trafficking, and function. While specific functions vary among family members, DPY19L3 has been specifically linked to the C-mannosylation of RPE-spondin (RPESP) . DPY19L2 has received particular attention in reproductive biology research, with studies suggesting its role in sperm head formation and male fertility. The protein appears to be involved in the attachment of the acrosome to the nuclear envelope during spermatogenesis, and mutations in the DPY19L2 gene have been associated with globozoospermia, a condition characterized by round-headed sperm with acrosomal defects . Meanwhile, other family members likely have distinct tissue-specific functions that remain under active investigation.

What criteria should guide DPY-19 antibody selection for specific applications?

When selecting a DPY-19 antibody, researchers should consider several critical factors:

• Target specificity: Determine whether you need an antibody specific to one DPY-19 family member or one that recognizes conserved regions. For instance, antibodies targeting the middle region of DPY19L2 may offer higher specificity than those targeting highly conserved domains .

• Application compatibility: Verify the antibody's validated applications. The DPY19L2 antibody ABIN2786329, for example, is specifically validated for Western blotting , while other antibodies may be validated for additional techniques like ELISA, immunofluorescence, or immunohistochemistry.

• Species reactivity: Confirm compatibility with your experimental model. Some antibodies show broad cross-reactivity (e.g., the ABIN2786329 antibody shows predicted reactivity with human, rat, cow, dog, guinea pig, horse, mouse, and rabbit DPY19L2 orthologs) .

• Epitope location: Consider whether you need an antibody targeting specific protein regions. Available DPY19L2 antibodies target various regions including AA 101-200, AA 599-749, AA 611-660, and AA 642-671 .

• Conjugation needs: Determine if you require unconjugated antibodies or those conjugated to specific tags (HRP, FITC, biotin) based on your detection system .

These considerations should guide selection to ensure optimal performance in your specific experimental context.

How should DPY-19 antibodies be validated for research applications?

Proper validation of DPY-19 antibodies requires a systematic approach:

• Western blot validation: The primary validation method for antibodies like ABIN2786329 involves Western blot analysis using appropriate cell lysates expressing the target protein . Look for bands of expected molecular weight and confirm specificity.

• Positive and negative controls: Include samples with known expression levels of the target DPY-19 protein. For negative controls, use samples from knockout models or cell lines with confirmed absence of the target.

• Peptide competition assay: Pre-incubate the antibody with its immunogenic peptide (such as the synthetic peptide directed toward the middle region of human DPY19L2) to confirm binding specificity.

• Cross-validation with different antibodies: Compare results using antibodies targeting different epitopes of the same protein to confirm consistency.

• Recombinant expression systems: Validate using overexpression systems such as the established HT1080-RPESP-MH cell line approach described for RPESP studies in conjunction with DPY19L proteins .

Complete validation should include documentation of optimal working conditions, including concentrations, incubation times, and buffer compositions for each application.

What experimental controls are essential when working with DPY-19 antibodies?

When conducting experiments with DPY-19 antibodies, implementing appropriate controls is crucial:

• Positive expression control: Include samples with confirmed expression of the target protein. For DPY19L2 antibodies, appropriate cell lysates expressing the protein should be used as demonstrated in the validation of ABIN2786329 .

• Negative control samples: Utilize samples lacking the target protein, such as:

  • Knockout/knockdown models (e.g., cells with CRISPR-edited DPY19L genes)

  • Cell lines known not to express the target

  • Control transfected cells (e.g., HT1080-neo cells as used in DPY19L3 studies)

• Isotype controls: Include antibodies of the same isotype but irrelevant specificity to identify non-specific binding.

• Secondary antibody-only control: Omit primary antibody to assess background from secondary antibody binding.

• Peptide blocking control: Pre-incubate antibody with immunizing peptide to confirm signal specificity.

• Cross-reactivity controls: When studying one DPY-19 family member, include samples expressing other family members to assess potential cross-reactivity, particularly important given the sequence similarity between DPY19L1-4 .

These controls help ensure that observed signals genuinely represent the intended target rather than artifacts or cross-reactions.

What is the optimal Western blot protocol for detecting DPY-19 proteins?

Based on methodologies described in the research literature, the following optimized Western blot protocol is recommended for DPY-19 protein detection:

• Sample preparation:

  • Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, and 1 mM phenylmethylsulfonyl fluoride

  • Sonicate samples (20 kHz, 50 W, 10 sec, twice) at 4°C

  • Centrifuge at 16,100 × g for 10 min at 4°C to remove debris

  • Quantify protein concentration (e.g., using Coomassie Brilliant Blue G-250 staining)

• Gel electrophoresis:

  • Add loading buffer containing 350 mM Tris-HCl (pH 6.8), 30% glycerol, 0.012% bromophenol blue, 6% SDS, and 30% 2-mercaptoethanol

  • Heat samples at 95°C for 3 minutes

  • Load 15-20 μg protein per lane on 12.5% SDS-polyacrylamide gels

  • Run at 100-120V until adequate separation

• Protein transfer and detection:

  • Transfer proteins to PVDF membranes

  • Block with TBST containing 5% nonfat dry milk

  • Incubate with primary DPY-19 antibody (e.g., anti-DPY19L2 at 1:1000 dilution)

  • Wash with TBST and incubate with appropriate HRP-conjugated secondary antibody

  • Develop using enhanced chemiluminescence

• Special considerations:

  • For glycoproteins like DPY-19 family members, sample deglycosylation may be necessary for accurate molecular weight determination

  • Gradient gels (4-15%) may provide better resolution of high molecular weight DPY-19 proteins

  • Transfer times may need optimization for these large transmembrane proteins

This protocol should be further optimized based on the specific DPY-19 family member being targeted and the antibody being used.

How can cellular expression of DPY-19 proteins be analyzed effectively?

Several complementary approaches can be employed to analyze DPY-19 protein expression in cellular contexts:

• Stable cell line generation:

  • Establish permanent cell lines expressing tagged DPY-19 proteins following the approach described for RPESP-Myc-His6 in HT1080 cells

  • Transfect cells with appropriate expression vectors (e.g., pCI-neo for mammalian cells, pMT-PURO for Drosophila S2 cells)

  • Select stable transfectants using appropriate antibiotics (e.g., 400 μg/ml G418)

  • Verify expression by Western blot using tag-specific or DPY-19-specific antibodies

• Immunofluorescence microscopy:

  • Culture cells on coverslips, fix with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100

  • Block with 5% BSA and incubate with DPY-19 antibodies (e.g., unconjugated or FITC-conjugated anti-DPY19L2)

  • Co-stain with organelle markers to determine subcellular localization

  • Analyze using confocal microscopy for precise localization

• Flow cytometry:

  • Prepare single-cell suspensions, fix/permeabilize as needed

  • Stain with fluorophore-conjugated DPY-19 antibodies or use primary/secondary antibody combinations

  • Analyze expression levels and heterogeneity across cell populations

• RT-qPCR complementation:

  • Analyze mRNA expression in parallel with protein detection

  • Design primers specific to individual DPY-19 family members

  • Correlate transcript and protein expression levels

These methods should be selected based on research questions and available resources, with combinations of approaches providing the most comprehensive analysis.

What approaches can be used to study DPY-19-mediated C-mannosylation?

Investigating DPY-19-mediated C-mannosylation requires specialized approaches that can detect this post-translational modification:

• Recombinant protein expression systems:

  • Express potential substrate proteins with epitope tags (e.g., Myc-His6) in appropriate cell systems

  • Co-express with DPY-19 family members (e.g., using pIZ/V5-his vectors containing DPY19L1-4 cDNAs)

  • Establish control cell lines using empty vectors (e.g., HT1080-neo) for comparison

• Mass spectrometry-based detection:

  • Purify candidate substrate proteins using affinity chromatography

  • Perform tryptic digestion and analyze peptides by LC-MS/MS

  • Look for mass shifts of +162 Da on tryptophan residues, indicating C-mannosylation

  • Compare spectra from proteins expressed with and without DPY-19 proteins

• Functional assays:

  • Compare biological activities of wild-type and mutant proteins (with tryptophan-to-alanine substitutions at potential C-mannosylation sites)

  • Assess protein stability, localization, and interaction capabilities

  • Evaluate phenotypic effects of disrupting C-mannosylation

• Glycosidase sensitivity testing:

  • Treat purified proteins with various glycosidases

  • C-mannosylation (unlike N- and O-glycosylation) is resistant to most enzymatic deglycosylation

  • Analyze mobility shifts by SDS-PAGE before and after treatment

These methodologies can be combined to provide comprehensive evidence of DPY-19-mediated C-mannosylation of target proteins.

How can contradictory results with DPY-19 antibodies be reconciled?

When researchers encounter contradictory results using different DPY-19 antibodies, a systematic troubleshooting approach should be implemented:

• Epitope mapping analysis:

  • Compare the epitopes recognized by different antibodies (e.g., middle region vs. C-terminal region of DPY19L2)

  • Consider whether post-translational modifications, protein folding, or proteolytic processing might differentially affect epitope accessibility

• Cross-validation with orthogonal methods:

  • Implement mRNA detection methods like RT-qPCR or RNA-seq

  • Use tagged recombinant proteins and detect via the tag rather than the protein itself

  • Apply CRISPR/Cas9 knockout controls to confirm specificity of signals

• Antibody validation status assessment:

  • Review validation data for each antibody (e.g., Western blot validation as reported for ABIN2786329)

  • Consider previously validated applications (some antibodies work well for Western blot but poorly for immunohistochemistry)

  • Test new lots of antibodies against previous lots if performance has changed

• Sample preparation variations:

  • Compare different lysis conditions that might affect protein conformation or solubility

  • Evaluate fixation methods that could impact epitope accessibility

  • Test native versus denaturing conditions depending on antibody epitope characteristics

• Systematic testing table:

This methodical approach can help identify the source of discrepancies and determine which antibody provides the most reliable results for specific experimental contexts.

What advanced techniques can reveal DPY-19 protein interactions and complexes?

To investigate DPY-19 protein interactions and complexes, researchers can employ several sophisticated techniques:

• Co-immunoprecipitation with mass spectrometry:

  • Use validated DPY-19 antibodies (such as those against DPY19L2) for immunoprecipitation

  • Alternatively, use epitope-tagged DPY-19 constructs expressed in model cell lines

  • Analyze precipitated complexes by LC-MS/MS to identify interacting partners

  • Verify key interactions with reverse co-IP and Western blotting

• Proximity labeling approaches:

  • Generate BioID or TurboID fusions with DPY-19 family proteins

  • Express in relevant cell types and activate biotinylation

  • Capture biotinylated proximal proteins and identify by mass spectrometry

  • This approach is particularly valuable for membrane proteins like DPY-19 family members

• FRET/BRET analysis:

  • Create fluorescent protein fusions with DPY-19 and candidate interactors

  • Measure energy transfer to detect interactions within 10 nm

  • Particularly useful for studying dynamics of interactions in living cells

  • Can distinguish direct interactions from co-complex membership

• Cross-linking mass spectrometry:

  • Apply membrane-permeable cross-linkers to stabilize transient interactions

  • Enrich DPY-19 complexes by immunoprecipitation

  • Identify cross-linked peptides by specialized MS/MS analysis

  • Provides detailed information about interaction interfaces

• Mammalian two-hybrid or split-reporter assays:

  • Adapt two-hybrid principles to mammalian expression systems

  • Use complementary fragments of luciferase or fluorescent proteins fused to potential interactors

  • Signal generation indicates protein-protein interaction

  • Allows high-throughput screening for novel interactions

These techniques provide complementary information about the composition, dynamics, and biological significance of DPY-19 protein complexes in cellular contexts.

How can researchers investigate tissue-specific roles of DPY-19 proteins?

Investigating tissue-specific roles of DPY-19 family proteins requires integrated approaches combining expression analysis with functional studies:

• Tissue expression profiling:

  • Analyze protein expression across tissues using validated antibodies for immunohistochemistry or Western blotting

  • Compare expression patterns of different family members (DPY19L1-4)

  • Correlate with publicly available RNA-seq databases for transcript-level validation

  • Pay particular attention to tissues with expression of potential substrate proteins

• Conditional knockout models:

  • Generate tissue-specific Cre-loxP conditional knockout models for individual DPY-19 genes

  • Analyze phenotypic consequences in specific tissues

  • For reproductive studies of DPY19L2, focus on germline-specific knockouts

  • Confirm protein absence using validated antibodies

• Single-cell analyses:

  • Perform single-cell RNA-seq to identify cell populations expressing DPY-19 family members

  • Follow up with antibody-based methods like single-cell Western blot or mass cytometry

  • Identify co-expression patterns with potential substrate proteins

  • Characterize cell type-specific regulatory mechanisms

• Tissue-specific substrate identification:

  • Adapt C-mannosylation detection methods to tissue samples

  • Compare C-mannosylation profiles between wild-type and DPY-19-deficient tissues

  • Analyze phenotypic consequences of mutation of specific C-mannosylation sites in tissue contexts

• Functional rescue experiments:

  • In tissue-specific knockout models, perform rescue experiments with:

    • Wild-type DPY-19 proteins

    • Catalytically inactive mutants

    • Tissue-specific promoters driving expression

  • Analyze the extent of phenotypic rescue to determine tissue-specific requirements

These integrated approaches can reveal both redundant and unique functions of DPY-19 family proteins across different tissues and cell types.

What is known about DPY-19 proteins in human disease contexts?

While research on DPY-19 proteins in disease contexts is still emerging, several associations have been identified:

Further research using validated antibodies against DPY-19 family members will be crucial for expanding our understanding of these proteins in various disease contexts.

What methods are recommended for analyzing pathogenic variants in DPY-19 genes?

Comprehensive analysis of pathogenic variants in DPY-19 genes requires integration of multiple methodological approaches:

• Genomic analysis techniques:

  • Next-generation sequencing (exome or genome) to identify point mutations

  • Multiplex ligation-dependent probe amplification (MLPA) or array comparative genomic hybridization (aCGH) to detect larger deletions/duplications

  • Long-read sequencing technologies to characterize complex structural variants

  • Specific attention to the DPY19L2 locus, which has been associated with recurrent deletions due to flanking segmental duplications

• Variant classification framework:

  • Assess population frequency in databases like gnomAD

  • Evaluate evolutionary conservation across species (noting the high conservation of DPY19L2 across mammals)

  • Apply in silico prediction tools for missense variants

  • Consider gene-specific features like domain structure and known functional regions

• Functional validation approaches:

  • Express variant proteins in cellular models

  • Assess protein localization using immunofluorescence with validated antibodies

  • Measure C-mannosyltransferase activity using mass spectrometry

  • Evaluate effects on known substrates and cellular processes

• Clinical correlation analysis:

  • Establish genotype-phenotype correlations through systematic clinical assessment

  • For DPY19L2, correlate variants with detailed sperm morphology and fertility outcomes

  • For other family members, consider broader phenotypic spectrum based on expression patterns

• Model systems for variant testing:

  • Generate CRISPR/Cas9 knock-in models carrying specific variants

  • Assess tissue-specific effects in models that recapitulate human expression patterns

  • Perform rescue experiments with wild-type protein to confirm pathogenicity

These integrated approaches provide a comprehensive framework for interpreting the clinical significance of variants in DPY-19 family genes, crucial for accurate genetic counseling and potential therapeutic development.

What emerging technologies might advance DPY-19 research?

Several cutting-edge technologies hold promise for advancing our understanding of DPY-19 proteins:

• Cryo-electron microscopy (Cryo-EM):

  • Determination of DPY-19 protein structures at near-atomic resolution

  • Visualization of C-mannosyltransferase mechanism

  • Analysis of structural changes induced by pathogenic variants

  • Characterization of substrate binding sites and specificity determinants

• Advanced glycoproteomics:

  • Targeted mass spectrometry approaches specific for C-mannosylated tryptophan residues

  • Techniques for enrichment of C-mannosylated peptides from complex samples

  • Integration with proteomics to identify the complete "C-mannosylome" in different tissues

  • Quantitative approaches to measure changes in C-mannosylation under different conditions

• Spatial transcriptomics and proteomics:

  • High-resolution mapping of DPY-19 expression in tissues

  • Correlation with substrate proteins at subcellular resolution

  • Analysis of C-mannosylation patterns in tissue contexts

  • Integration with single-cell approaches for comprehensive mapping

• Organoid and advanced cell culture models:

  • Study of DPY-19 function in physiologically relevant 3D models

  • Patient-derived organoids for analysis of pathogenic variants

  • Co-culture systems to examine intercellular effects of C-mannosylation

  • Development of high-throughput screening platforms in these models

• Artificial intelligence applications:

  • Prediction of C-mannosylation sites beyond the W-X-X-W motif

  • Modeling of substrate-enzyme interactions based on sequence features

  • Integration of multi-omics data to identify regulatory networks

  • Design of selective inhibitors or activators of specific DPY-19 family members

These technologies, combined with continued development of specific research reagents like the antibodies described in the search results , will drive significant advances in our understanding of DPY-19 biology and C-mannosylation.

How might improved antibody development enhance DPY-19 research?

Advancements in antibody technology could substantially enhance DPY-19 research through several key approaches:

• Epitope-specific antibody development:

  • Generation of antibodies that specifically distinguish between DPY19L1, DPY19L2, DPY19L3, and DPY19L4

  • Development of conformation-specific antibodies that recognize native protein structures

  • Creation of antibodies against post-translationally modified forms of DPY-19 proteins

  • Design of antibodies targeting functionally important domains with minimal cross-reactivity

• Advanced validation strategies:

  • Implementation of CRISPR knockout validation in multiple cell types

  • Mass spectrometry confirmation of immunoprecipitated proteins

  • Comprehensive cross-reactivity testing against all family members

  • Detailed epitope mapping using peptide arrays or hydrogen-deuterium exchange

• Specialized research applications:

  • Development of antibodies optimized for super-resolution microscopy

  • Proximity labeling antibody conjugates for mapping DPY-19 interactomes

  • Antibodies designed for intracellular delivery to track proteins in living cells

  • Antibody-based sensors that detect conformational changes in DPY-19 proteins

• Technical improvements in antibody properties:

  • Enhanced detection sensitivity through signal amplification methods

  • Increased specificity through recombinant antibody engineering

  • Improved lot-to-lot consistency through recombinant production

  • Extended half-life antibody variants for prolonged experimental applications similar to what Spyre Therapeutics is developing for other targets

• Application-optimized formats:

  • Single-chain variable fragments (scFvs) for improved tissue penetration

  • Nanobodies for accessing sterically hindered epitopes

  • Bispecific antibodies for co-detection of DPY-19 and substrate proteins

  • Site-specifically conjugated antibodies with precisely controlled labeling

These advancements would address current limitations in DPY-19 research by providing more specific and versatile tools for detecting, localizing, and functionally characterizing these important enzymes across diverse experimental contexts.